Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer
…, J Margery, F Guisier, A Vergnenegre, G Robinet… - Targeted Oncology, 2017 - Springer
Immune checkpoint inhibitors, notably antibodies targeting programmed death–1 (PD-1)
and programmed death ligand–1 (PD-L1), have modified the management of patients with …
and programmed death ligand–1 (PD-L1), have modified the management of patients with …
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled …
…, W Hilgers, H Lena, D Moro-Sibilot, G Robinet… - The Lancet, 2019 - thelancet.com
Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer …
…, Y Zhao, C Chen, L Koubkova, G Robinet… - The Lancet …, 2021 - thelancet.com
Background First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide)
showed a significant improvement in overall survival versus platinum–…
showed a significant improvement in overall survival versus platinum–…
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a …
…, N Baize, R Garcia-Campelo, G Robinet… - The lancet …, 2012 - thelancet.com
Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
…, Y Oe, A Chella, A Chopra, G Robinet… - The Lancet …, 2018 - thelancet.com
Background Immune checkpoint inhibitors are a new standard of care for patients with
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic …
[HTML][HTML] Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non–small-cell lung cancer
…, MJ Krzakowski, G Robinet… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Increased hepatocyte growth factor/MET signaling is associated with poor prognosis
and acquired resistance to epidermal growth factor receptor (EGFR)–targeted drugs in …
and acquired resistance to epidermal growth factor receptor (EGFR)–targeted drugs in …
[HTML][HTML] Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain …
Purpose To determine if the timing of whole brain radiotherapy (WBRT) with respect to
chemotherapy with cisplatin and vinorelbine would influence survival in patients with non-small-…
chemotherapy with cisplatin and vinorelbine would influence survival in patients with non-small-…
Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non–small-cell lung cancer: Groupe …
P Fournel, G Robinet, P Thomas, PJ Souquet… - Journal of clinical …, 2005 - ascopubs.org
Purpose We conducted a phase III study to compare the survival impact of concurrent versus
sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage …
sequential treatment with radiotherapy (RT) and chemotherapy (CT) in unresectable stage …
Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized …
…, SJ Antonia, S Le Moulec, G Robinet… - JAMA …, 2020 - jamanetwork.com
… Dr Robinet reports grants and personal fees from AstraZeneca, Roche, Merck Sharp &
Dohme, and Bristol-Myers Squibb, and personal fees from Bayer. Dr Natale reports that his …
Dohme, and Bristol-Myers Squibb, and personal fees from Bayer. Dr Natale reports that his …
[HTML][HTML] Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing …
R Rosell, G Robinet, A Szczesna, R Ramlau… - Annals of oncology, 2008 - Elsevier
Background The Lung Cancer Cetuximab Study is an open-label, randomized phase II pilot
study of cisplatin and vinorelbine combined with the epidermal growth factor receptor (EGFR)…
study of cisplatin and vinorelbine combined with the epidermal growth factor receptor (EGFR)…